Cover Image
市場調查報告書

輻射中毒 (輻射病·急性輻射症候群) :開發中產品分析

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229758
出版日期 內容資訊 英文 212 Pages
訂單完成後即時交付
價格
Back to Top
輻射中毒 (輻射病·急性輻射症候群) :開發中產品分析 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 212 Pages
簡介

輻射中毒(輻射病,急性游離輻射症候群)是在非常短的期間內(通常是僅數分鐘內)全身(或大範圍)穿過了高劑量的輻射線所引起的急性疾病。主要的原因是特別組織的未成熟實質性幹細胞的減少。常見的症狀有口鼻·牙齦的出血、血便、瘀傷、精神混亂、脫水、腹瀉、昏厥、疲勞等症狀。

本報告提供輻射中毒 (輻射病·急性輻射症候群) 的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

輻射中毒 (輻射病·急性輻射症候群)的概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

輻射中毒 (輻射病·急性輻射症候群) :企業開發中的治療藥

輻射中毒 (輻射病·急性輻射症候群) :大學/機關研究中的治療藥

輻射中毒 (輻射病·急性輻射症候群) :開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

輻射中毒 (輻射病·急性輻射症候群) :企業開發中的產品

輻射中毒 (輻射病·急性輻射症候群) :大學/機關研究中的產品

輻射中毒 (輻射病·急性輻射症候群)的治療藥的開發企業

  • Aeolus Pharmaceuticals, Inc.
  • Angion Biomedica Corp.
  • Atox Bio Inc.
  • Avaxia Biologics, Inc.
  • Bolder Biotechnology, Inc.
  • Caladrius Biosciences, Inc.
  • Cellerant Therapeutics, Inc.
  • Cellphire, Inc.
  • Chrysalis BioTherapeutics, Inc.
  • Cleveland BioLabs, Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Diffusion Pharmaceuticals Inc.
  • Eli Lilly and Company
  • GNI Group Ltd.
  • Humanetics Corporation
  • INSYS Therapeutics, Inc.
  • Meabco A/S
  • Neumedicines Inc.
  • Onconova Therapeutics, Inc.
  • PharmaIN Corporation
  • Pluristem Therapeutics Inc.
  • ProCertus BioPharm Inc.
  • RDD Pharma Ltd.
  • RedHill Biopharma Ltd.
  • RxBio, Inc.
  • Soligenix, Inc.
  • Stemedica Cell Technologies, Inc.
  • Terapio Corporation
  • Tonix Pharmaceuticals Holding Corp.

輻射中毒 (輻射病·急性輻射症候群) :治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

輻射中毒 (輻射病·急性輻射症候群) :最近的開發平台趨勢

輻射中毒 (輻射病·急性輻射症候群) :暫停中的計劃

輻射中毒 (輻射病·急性輻射症候群) :開發中止的產品

輻射中毒 (輻射病·急性輻射症候群) :產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8456IDB

Summary

Global Markets Direct's, 'Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2016', provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
  • The report reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics and enlists all their major and minor projects
  • The report assesses Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview
  • Therapeutics Development
    • Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview
    • Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Development by Companies
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Investigation by Universities/Institutes
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Development by Companies
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Investigation by Universities/Institutes
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development
    • Aeolus Pharmaceuticals, Inc.
    • Angion Biomedica Corp.
    • Atox Bio Ltd.
    • BCN Biosciences L.L.C.
    • Bolder Biotechnology, Inc.
    • Cellerant Therapeutics, Inc.
    • Cellphire, Inc.
    • Chrysalis BioTherapeutics, Inc.
    • Cleveland BioLabs, Inc.
    • Cumberland Pharmaceuticals, Inc.
    • Diffusion Pharmaceuticals Inc.
    • GNI Group Ltd.
    • Humanetics Corporation
    • INSYS Therapeutics, Inc.
    • Meabco A/S
    • Neumedicines Inc.
    • Nohla Therapeutics Inc.
    • Onconova Therapeutics, Inc.
    • Original BioMedicals Co. Ltd.
    • PharmaIN Corporation
    • Pluristem Therapeutics Inc.
    • RDD Pharma Ltd.
    • Reata Pharmaceuticals, Inc.
    • RedHill Biopharma Ltd.
    • RxBio, Inc.
    • SK Chemicals Co., Ltd.
    • Soligenix, Inc.
    • Stemedica Cell Technologies, Inc.
    • Terapio Corporation
    • Tonix Pharmaceuticals Holding Corp.
    • Vida Therapeutics Inc.
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • A-02 - Drug Profile
    • AB-103 - Drug Profile
    • ABC-294640 - Drug Profile
    • AEOL-10150 - Drug Profile
    • AEOL-10171 - Drug Profile
    • amifostine - Drug Profile
    • Antisense RNAi Oligonucleotide for Influenza, Rheumatoid Arthritis and Radiation-Induced Fibrosis - Drug Profile
    • AVMOC-001 - Drug Profile
    • BB-3 - Drug Profile
    • BBT-007 - Drug Profile
    • BBT-015 - Drug Profile
    • BBT-018 - Drug Profile
    • BBT-059 - Drug Profile
    • BCN-057 - Drug Profile
    • BIO-300 - Drug Profile
    • BMX-001 - Drug Profile
    • BPC-2 - Drug Profile
    • C-2E2 - Drug Profile
    • C-2E5 - Drug Profile
    • Cell Therapy for Acute Radiation Syndrome - Drug Profile
    • cerium oxide - Drug Profile
    • CLT-009 - Drug Profile
    • Des-Asp Angiotensin 1 - Drug Profile
    • Drug to Antagonize Adenosine A2A Receptor for Radiation Dermatitis - Drug Profile
    • entolimod - Drug Profile
    • EWA-001 - Drug Profile
    • HSJ-0017 - Drug Profile
    • JP4-039 - Drug Profile
    • LGM-2605 - Drug Profile
    • m-2A2 - Drug Profile
    • molgramostim - Drug Profile
    • monosodium luminol - Drug Profile
    • NMIL-121 - Drug Profile
    • omaveloxolone - Drug Profile
    • ondansetron hydrochloride - Drug Profile
    • ondansetron hydrochloride CR - Drug Profile
    • Peptide to Agonize GHSR-1a for Acute Ischemic Stroke, Acute Radiation Syndrome, and Sepsis - Drug Profile
    • pirfenidone - Drug Profile
    • PLXR-18 - Drug Profile
    • RDD-2007 - Drug Profile
    • recilisib sodium - Drug Profile
    • Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile
    • Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile
    • Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile
    • Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile
    • RES-529 - Drug Profile
    • RP-239X - Drug Profile
    • rusalatide acetate - Drug Profile
    • Rx-100 - Drug Profile
    • SGX-201 - Drug Profile
    • SGX-202 - Drug Profile
    • SKI-2162 - Drug Profile
    • Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury - Drug Profile
    • Small Molecules for Radiation and Chemical Toxicity - Drug Profile
    • Small Molecules for Radiation Toxicity - Drug Profile
    • Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile
    • ST-266 - Drug Profile
    • ST-7 - Drug Profile
    • Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile
    • SY-303A - Drug Profile
    • SY-513 - Drug Profile
    • SYGN-305 - Drug Profile
    • SYGN-399 - Drug Profile
    • Thrombosomes - Drug Profile
    • TPO-7630 - Drug Profile
    • TPO-7640 - Drug Profile
    • VEDA-1209 - Drug Profile
    • VTI-1000 Series - Drug Profile
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2016
  • Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Ltd., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by BCN Biosciences L.L.C., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology, Inc., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics, Inc., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellphire, Inc., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Chrysalis BioTherapeutics, Inc., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs, Inc., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cumberland Pharmaceuticals, Inc., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by GNI Group Ltd., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corporation, H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by INSYS Therapeutics, Inc., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Nohla Therapeutics Inc., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics, Inc., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Original BioMedicals Co. Ltd., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by PharmaIN Corporation, H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RDD Pharma Ltd., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Reata Pharmaceuticals, Inc., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RedHill Biopharma Ltd., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio, Inc., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by SK Chemicals Co., Ltd., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix, Inc., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Stemedica Cell Technologies, Inc., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Terapio Corporation, H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Vida Therapeutics Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..1), H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..2), H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..3), H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..4), H2 2016
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2016
  • Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top